Alcohol is an important risk factor for upper aerodigestive cancers and is principally metabolized by alcohol dehydrogenase (ADH) enzymes. We have investigated six ADH genetic variants in over 3,800 aerodigestive cancer cases and 5,200 controls from three individual studies. Gene variants rs1229984 (ADH1B) and rs1573496 (ADH7) were significantly protective against aerodigestive cancer in each individual study and overall (P ¼ 10 À10 and 10 À9 , respectively). These effects became more apparent with increasing alcohol consumption (P for trend ¼ 0.0002 and 0.065, respectively). Both gene effects were independent of each other, implying that multiple ADH genes may be involved in upper aerodigestive cancer etiology.
Alcohol is an important risk factor for upper aerodigestive cancers and is principally metabolized by alcohol dehydrogenase (ADH) enzymes. We have investigated six ADH genetic variants in over 3,800 aerodigestive cancer cases and 5,200 controls from three individual studies. Gene variants rs1229984 (ADH1B) and rs1573496 (ADH7) were significantly protective against aerodigestive cancer in each individual study and overall (P ¼ 10 À10 and 10 À9 , respectively). These effects became more apparent with increasing alcohol consumption (P for trend ¼ 0.0002 and 0.065, respectively). Both gene effects were independent of each other, implying that multiple ADH genes may be involved in upper aerodigestive cancer etiology.
The alcohol dehydrogenase (ADH) pathway includes seven distinct ADH genes, a key candidate gene group for aerodigestive cancers [1] [2] [3] .
Studies of aerodigestive cancer in populations of European origin have focused on ADH1C with little evidence of any effect 4 . We previously reported an association for ADH1B R48H (rs1229984) in a central European (CE) population 5 and now consider the effect of this and five other ADH variants in an expanded study comprising 809 aerodigestive cancer cases and 2,586 controls from the CE study as well as a further 3,067 aerodigestive cancer cases and 2,692 controls from two other studies in Europe (ARCAGE study) and Latin America (LA study) (total of 3,876 cases and 5,278 controls). All three studies were coordinated by the International Agency for Research on Cancer (IARC) and followed a similar protocol (Supplementary Methods online). Of the 3,876 cases, 1,790 were cancers of the oral cavity or pharynx, 1,659 were cancers of the hypopharynx or larynx and 427 were cancers of the esophagus (Supplementary Table 1 online) . Cases with a histology other than squamous cell were excluded.
The HapMap Consortium has genotyped 163 SNPs in the vicinity of the ADH gene cluster with a minor allele frequency (MAF) of 4% or more in the CEPH Utah (CEU) population 6 . Inspection of the linkage disequilibrium (LD) pattern across this region indicates that ADH1A, ADH1B, ADH1C, ADH4, ADH5 and ADH6 are relatively highly correlated, whereas ADH7 showed little correlation with the remaining six ( Supplementary Fig. 1a online) . From all verified missense SNPs in the seven ADH genes found in both the NCBI SNP and SNP500 databases 7 , we selected eight that had a MAF 4 4% in the CEU population. Three missense SNPs in ADH4 (rs1126671, rs1126673 and rs1042364) were in strong LD, and thus were genotyped by the highly correlated tagging SNP rs1984362 (r 2 4 0.89). In total, we genotyped six genetic variants (five missense SNPs and one tagging SNP) in all three studies ( Table 1 and Supplementary Table 2 online).
In the pooled analysis on all 3,876 cases and 5,278 controls, four variants reported a significant association (Supplementary Table 3 online). The most prominent was with rs1229984 (in ADH1B; OR for codominant model ¼ 0.59 (95% CI ¼ 0.50-0.69); P under codominant model ¼ 8 Â 10 À10 ). This variant was significant in each of the three individual studies (CE: P ¼ 5 Â 10 À5 ; ARCAGE: P ¼ 1 Â 10 À4 ; LA: P ¼ 0.002). A second strongly significant finding in the pooled analysis was with rs1573496 (in ADH7; OR ¼ 0.69 (0.61-0.78); P ¼ 3 Â 10 À9 ), a new potential susceptibility gene for this cancer. This variant was also significant in each of the three individual studies (CE: P ¼ 1 Â 10 À7 ; ARCAGE: P ¼ 0.015; LA: P ¼ 0.008). Significant effects were also observed for both ADH1C variants: rs1693482 (OR ¼ 1.17 (1.09-1.26); P ¼ 2 Â 10 À5 ) and rs698 (OR ¼ 1.14 (1.06-1.23); P ¼ 3 Â 10 À4 ). These two variants were highly correlated in all three studies (D¢ 4 0.99, r 2 4 0.97, Supplementary Fig. 1b) , so we considered only rs1693482 for further analysis. A moderate increase in risk for this variant was observed in each of the three individual studies (CE: P ¼ 0.02; ARCAGE: P ¼ 0.002; LA:
Both rs1229984 (ADH1B) and rs1693482 (ADH1C) were in LD, with D¢ 4 0.75 in all three studies ( Supplementary Fig. 1b) . In order to determine the independence of each SNP, we repeated analysis of rs1693482 (ADH1C) excluding rs1229984[A] (ADH1B) carriers and vice versa (Supplementary Table 4a online). This indicated that the effect of rs1229984 (ADH1B) was not influenced by rs1693482 (ADH1C) and that the effect observed with rs1693482 (ADH1C) could not be explained solely by LD with rs1229984 (ADH1B). In contrast, there was little LD between rs1573496 (ADH7) and rs1229984 (ADH1B), with D¢ o 0.21 in all three studies (Supplementary Fig. 1b ). To illustrate their independence, we repeated analysis of rs1229984 (ADH1B) excluding carriers of rs1573496[C] (ADH7) and vice versa. As expected considering the lack of LD between these two SNPs, the risk estimates remained very similar to those based on the complete dataset ( Supplementary Table 4b ).
Subsequently, we focused on the effects of rs1229984[A] (ADH1B) and rs1573496[C] (ADH7) after stratifying by site of cancer, age, alcohol consumption, tobacco smoking and study ( Fig. 1 ). Significant heterogeneity (P ¼ 0.001) for rs1229984 (ADH1B) was observed by cancer site with a reduction in risk of between two-and threefold for oral and pharyngeal cancer (OR ¼ 0.45 (0.35-0.57)) and esophageal cancer (OR ¼ 0.34 (0.20-0.56)), as opposed to a 30% decrease in risk for larynx cancer (OR ¼ 0.71 (0.57-0.88)). We observed significant heterogeneity by site for rs1573496 (ADH7) (P ¼ 0.023), with the most pronounced protective effect being for esophageal cancer (OR ¼ 0.45 (0.32-0.64)). For both gene variants, there was an increasing protective effect with increasing alcohol consumption. For rs1229984 (ADH1B), we did not observe any effect among never drinkers (OR ¼ 1.02 (0.66-1.56)), whereas we observed an over twofold effect among those who drank above the median level of alcohol in each study (OR ¼ 0.42 (0.31-0.56); P for trend ¼ 0.0002). Similarly, for rs1573496 (ADH7), no effect was detected among never drinkers and a 40% decrease in risk was observed for heavy drinkers (OR ¼ 0.61 (0.50-0.75); P for trend ¼ 0.065). The effect of rs1229984 (ADH1B) was consistent across the three studies, whereas the effect of rs1573496 (ADH7) varied from OR ¼ 0.54 (0.43-0.69) in the CE study to 0.79 (0.64-0.98) for the ARCAGE study (P for heterogeneity ¼ 0.08). Any potential heterogeneity seemed to be explained by a higher proportion of esophageal cancer cases in the CE study (21%) as opposed to the LA study (9%) and the ARCAGE study (8%). When esophageal cancer cases were excluded from this analysis, no betweenstudy heterogeneity was apparent for rs1573496 (ADH7) (P for heterogeneity ¼ 0.38). 
B R I E F C O M M U N I C A T I O N S
We also analyzed the effect of carrying the rs1693482 (ADH1C) G/A or A/A variant after stratifying by site of cancer, age, alcohol consumption, tobacco smoking and study ( Supplementary Fig. 2 online) . No notable heterogeneity by any of these factors was observed.
Finally, we assessed the combined effect of carrying either one or both of the rare gene variants from rs1229984 (ADH1B) and rs1573496 (ADH7). These results provide strong evidence that both ADH1B and ADH7 have an important association with susceptibility to aerodigestive cancer. The strong similarity of the results from different studies argues against population stratification or other biases. These effects seem to be relevant for all aerodigestive tract subsites, although they may be more prominent for esophageal cancer, and they both seem to be dependent on alcohol consumption-that is, among nondrinkers, the gene variants have little or no effect on disease risk, whereas among alcohol drinkers, the protective effect is more apparent at higher alcohol intake. Furthermore, neither gene variant seemed to be consistently associated with the amount of alcohol consumed in controls (data not shown), indicating that any protective effect from these gene-environment interactions is likely to be due to their role in changing the carcinogenic effect of alcohol beverages.
Whether we have studied the causal variants in these two genes or whether our associations are secondary to other causal variants is unknown. rs1229984 (ADH1B) G/A heterozygotes and A/A homozygotes are known to metabolize ethanol up to 100 times quicker than the common rs1229984 (ADH1B) G/G homozygote 4 , providing support that quick eradication of ethanol, and therefore lower local exposure, may be protective 5 . The potential role of ADH7 is unclear, however, although variants in this gene may also influence ethanol metabolism 8 . Given the limited association between ADH7 and other ADH genes ( Supplementary Fig. 1a) , it would be expected that the causal association for this variant resides in the region of ADH7.
In summary, our analysis of six ADH genetic variants in over 3,800 cases and 5,000 controls has identified two that are independently and strongly associated with aerodigestive cancers. Elucidation of these findings and further detailed characterization of this pathway in a large series of subjects seems warranted.
Note: Supplementary information is available on the Nature Genetics website.
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